Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Yoshikazu Kinoshita, Yuuichi Sakurai, Madoka Shiino, Kentaro Kudou, Akira Nishimura, Takuya Miyagi, Katsuhiko Iwakiri, Eiji Umegaki, Kiyoshi Ashida, Yoshikazu Kinoshita, Yuuichi Sakurai, Madoka Shiino, Kentaro Kudou, Akira Nishimura, Takuya Miyagi, Katsuhiko Iwakiri, Eiji Umegaki, Kiyoshi Ashida
Abstract
Background: For many patients, current treatments do not adequately resolve heartburn in nonerosive reflux disease (NERD).
Objective: To compare vonoprazan and placebo with respect to the frequency and severity of heartburn in patients with NERD.
Methods: This Phase III, double-blind, placebo-controlled, parallel-group, multicenter study included patients in Japan aged ≥20 years with Grade N or M NERD and recurrent acid reflux symptoms. Patients were blinded and randomized 1:1:1 to receive placebo or vonoprazan 10 mg or 20 mg. The primary efficacy outcome was the proportion of days without heartburn measured by patient scores during the 4-week treatment period.
Results: Eight hundred twenty-seven patients were randomized (placebo: n = 278, vonoprazan 10 mg: n = 278, and vonoprazan 20 mg: n = 271). Median proportion of days without heartburn was 7.4% (placebo), 10.3% (vonoprazan 10 mg), and 12.0% (vonoprazan 20 mg). Proportion of days without heartburn was not statistically significant between the vonoprazan and placebo groups (P = 0.2310 [10 mg] and P = 0.0504 [20 mg]). Mean severity of heartburn was significantly higher with placebo (median score = 1.070) than with vonoprazan 10 mg (median score = 0.990; P = 0.0440) and 20 mg (median score = 0.960; P = 0.0139). Patients whose symptoms improved at Week 2 experienced significantly increased proportion of days without heartburn and reduced mean severity of heartburn at Week 4 with vonoprazan compared with placebo (proportion of days without heartburn: P = 0.0004 [10 mg] and P = 0.0001 [20 mg] and mean severity: P < 0.0001 [10 mg] and P < 0.0001 [20 mg]). A significant difference in median proportion of days without heartburn was observed for vonoprazan 20 mg compared with placebo in patients with Grade M NERD. Incidence of treatment-emergent adverse events was 32.7% (placebo), 27.7% (vonoprazan 10 mg), and 28.0% (vonoprazan 20 mg).
Conclusions: Vonoprazan at doses of 10 mg and 20 mg are not superior to placebo with respect to proportion of days without heartburn, whereas the mean severity of heartburn is lower with vonoprazan compared with placebo in patients with NERD. ClinicalTrials.gov identifier: NCT01474369.
Keywords: NERD; gastroesophageal reflux; heartburn; nonerosive gastroesophageal reflux disease; potassium-competitive acid blockers; vonoprazan.
Figures
References
- Fass R., Fennerty M.B., Vakil N. Nonerosive reflux disease--current concepts and dilemmas. Am J Gastroenterol. 2001;96(2):303–314.
- Lee E.S. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Aliment Pharmacol Ther. 2009;30(2):154–164.
- Fock K.M. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008;23(1):8–22.
- Miwa H. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther. 2007;26(1):69–77.
- Shin J.M. Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438) J Pharmacol Exp Ther. 2011;339(2):412–420.
- Ashida K. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43(2):240–251.
- Murakami K. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439–1446.
- Takeda Takecab (vonoprazan tablets) package insert. Available at: . Accessed 28 Sep 2016.
- Hori Y. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335(1):231–238.
- Hori Y. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther. 2011;337(3):797–804.
- Sakurai Y. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. Clin Transl Gastroenterol. 2015;6:e94.
- Hongo M. Minimal changes in reflux esophagitis: red ones and white ones. J Gastroenterol. 2006;41(2):95–99.
- Hongo Ma.Y.H. Efficacy and safety of lansoprazole (AG-1749) 15 mg and 30 mg in Japanese patients with non-erosive reflux disease (NERD) - a phase III multicenter, double-blind, placebo-controlled trial. Jpn Pharmacol Ther. 2008;36(7):655–671.
- Adachi K. A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease. Dig Dis Sci. 2012;57(6):1609–1617.
- Shimatani T. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring. J Gastroenterol Hepatol. 2012;27(5):899–906.
- Miyamoto M., Manabe N., Haruma K. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy. Intern Med. 2010;49(15):1469–1476.
Source: PubMed